Nature11 个月
Optimal first-line therapy for NSCLC with EGFR mutations
The IPASS (Iressa Pan-Asia Study) is the first large randomized clinical trial that compared first-line EGFR TKI therapy with chemotherapy. 1 In this study, 1,217 Asian non-smokers or former light ...
Discovery of rapid COVID-19 replication mechanism could expand treatment options
Kim's team revealed that once COVID-19 invades human cells, it quickly modifies the structure and function ... that the virus ...